Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting C

Name: Phase 3 Topline: A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting C
Start: 2032-01-01

January 1, 2032

Company: Lyell Immunopharma, Inc. (LYEL)
Drug: rondecabtagene
Indication: Diffuse Large B Cell Lymphoma (DLBCL); Non-Hodgkin Lymphoma; Large B-cell Lymphoma

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting C — LYEL Phase 3 Readout | BioSniper